Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 139


Immunogenicity of a multiepitope plasmid DNA encoding T and B lymphocyte epitopes from latent membrane protein 2 (LMP2) of Epstein-Barr virus as a vaccine in mice.

Li W, Chen Q, Lin Q, Lv Y, Feng J, Liu J, Xu W, Chen S, Zhu X, Zhang L.

Protein Pept Lett. 2013 Oct;20(10):1136-43.


Expression of HPV6b L1/EBV LMP2 multiepitope and immunogenicity in mice.

Zhu S, Xue X, Liu J, Lu L, Zhao P, Wang J, Li W, Zhang L.

Acta Biochim Biophys Sin (Shanghai). 2010 Aug;42(8):515-21. doi: 10.1093/abbs/gmq054. Epub 2010 Jul 5.


Rational design of a multiepitope vaccine encoding T-lymphocyte epitopes for treatment of chronic hepatitis B virus infections.

Depla E, Van der Aa A, Livingston BD, Crimi C, Allosery K, De Brabandere V, Krakover J, Murthy S, Huang M, Power S, Babé L, Dahlberg C, McKinney D, Sette A, Southwood S, Philip R, Newman MJ, Meheus L.

J Virol. 2008 Jan;82(1):435-50. Epub 2007 Oct 17.


Therapeutic LMP1 polyepitope vaccine for EBV-associated Hodgkin disease and nasopharyngeal carcinoma.

Duraiswamy J, Sherritt M, Thomson S, Tellam J, Cooper L, Connolly G, Bharadwaj M, Khanna R.

Blood. 2003 Apr 15;101(8):3150-6. Epub 2002 Dec 5.


A novel tetrameric gp350 1-470 as a potential Epstein-Barr virus vaccine.

Cui X, Cao Z, Sen G, Chattopadhyay G, Fuller DH, Fuller JT, Snapper DM, Snow AL, Mond JJ, Snapper CM.

Vaccine. 2013 Jun 26;31(30):3039-45. doi: 10.1016/j.vaccine.2013.04.071. Epub 2013 May 9.


Protective immunity against Chlamydia trachomatis genital infection induced by a vaccine based on the major outer membrane multi-epitope human papillomavirus major capsid protein L1.

Xu W, Liu J, Gong W, Chen J, Zhu S, Zhang L.

Vaccine. 2011 Mar 24;29(15):2672-8. doi: 10.1016/j.vaccine.2010.12.132. Epub 2011 Feb 12.


Chimerically fused antigen rich of overlapped epitopes from latent membrane protein 2 (LMP2) of Epstein-Barr virus as a potential vaccine and diagnostic agent.

Lin X, Chen S, Xue X, Lu L, Zhu S, Li W, Chen X, Zhong X, Jiang P, Sename TS, Zheng Y, Zhang L.

Cell Mol Immunol. 2016 Jul;13(4):492-501. doi: 10.1038/cmi.2015.29. Epub 2015 Apr 13.


Identification and characterization of novel B-cell epitopes within EBV latent membrane protein 2 (LMP2).

Xue X, Zhu S, Li W, Chen J, Ou Q, Zheng M, Gong W, Zhang L.

Viral Immunol. 2011 Jun;24(3):227-36. doi: 10.1089/vim.2010.0092.


Novel Epstein-Barr virus-like particles incorporating gH/gL-EBNA1 or gB-LMP2 induce high neutralizing antibody titers and EBV-specific T-cell responses in immunized mice.

Perez EM, Foley J, Tison T, Silva R, Ogembo JG.

Oncotarget. 2017 Mar 21;8(12):19255-19273. doi: 10.18632/oncotarget.13770.


Recognition of Epstein-Barr virus-associated gastric carcinoma cells by cytotoxic T lymphocytes induced in vitro with autologous lymphoblastoid cell line and LMP2-derived, HLA-A24-restricted 9-mer peptide.

Okugawa K, Itoh T, Kawashima I, Takesako K, Mazda O, Nukaya I, Yano Y, Yamamoto Y, Yamagishi H, Ueda Y.

Oncol Rep. 2004 Oct;12(4):725-31.


Specific cellular immune responses in mice immunized with DNA, adeno-associated virus and adenoviral vaccines of Epstein-Barr virus-LMP2 alone or in combination.

Wang Z, Yang S, Zhou L, Du H, Mo W, Zeng Y.

Sci China Life Sci. 2011 Mar;54(3):263-6. doi: 10.1007/s11427-011-4147-0. Epub 2011 Mar 16.


Dendritic cells transduced with an adenovirus vector encoding Epstein-Barr virus latent membrane protein 2B: a new modality for vaccination.

Ranieri E, Herr W, Gambotto A, Olson W, Rowe D, Robbins PD, Kierstead LS, Watkins SC, Gesualdo L, Storkus WJ.

J Virol. 1999 Dec;73(12):10416-25.


A novel latent membrane 2 transcript expressed in Epstein-Barr virus-positive NK- and T-cell lymphoproliferative disease encodes a target for cellular immunotherapy.

Fox CP, Haigh TA, Taylor GS, Long HM, Lee SP, Shannon-Lowe C, O'Connor S, Bollard CM, Iqbal J, Chan WC, Rickinson AB, Bell AI, Rowe M.

Blood. 2010 Nov 11;116(19):3695-704. doi: 10.1182/blood-2010-06-292268. Epub 2010 Jul 29.


DNA-mediated immunization of glycoprotein 350 of Epstein-Barr virus induces the effective humoral and cellular immune responses against the antigen.

Jung S, Chung YK, Chang SH, Kim J, Kim HR, Jang HS, Lee JC, Chung GH, Jang YS.

Mol Cells. 2001 Aug 31;12(1):41-9.


HLA A2.1-restricted cytotoxic T cells recognizing a range of Epstein-Barr virus isolates through a defined epitope in latent membrane protein LMP2.

Lee SP, Thomas WA, Murray RJ, Khanim F, Kaur S, Young LS, Rowe M, Kurilla M, Rickinson AB.

J Virol. 1993 Dec;67(12):7428-35.


Supplemental Content

Support Center